|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1998-7-14
|
|
pubmed:abstractText |
Lipid-lowering drugs as 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors and cholestyramine are effective in reducing cardiovascular morbidity both in primary and secondary prevention. Patient compliance is an important determinant of the outcome of therapy. This study was designed to compare compliance with tolerance and lipid-lowering effectiveness of pravastatin and/or cholestyramine in primary care.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0954-6820
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
243
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
373-80
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:9651560-Adult,
pubmed-meshheading:9651560-Aged,
pubmed-meshheading:9651560-Anticholesteremic Agents,
pubmed-meshheading:9651560-Cholestyramine Resin,
pubmed-meshheading:9651560-Female,
pubmed-meshheading:9651560-Humans,
pubmed-meshheading:9651560-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:9651560-Hypercholesterolemia,
pubmed-meshheading:9651560-Lipids,
pubmed-meshheading:9651560-Male,
pubmed-meshheading:9651560-Middle Aged,
pubmed-meshheading:9651560-Patient Compliance,
pubmed-meshheading:9651560-Pravastatin,
pubmed-meshheading:9651560-Primary Health Care,
pubmed-meshheading:9651560-Sex Factors,
pubmed-meshheading:9651560-Sweden,
pubmed-meshheading:9651560-Treatment Outcome
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care.
|
|
pubmed:affiliation |
Centre for metabolism and endocrinology, Huddinge University Hospital, Stockholm, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
